A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) - Join Clinical Trial NCTNCT06503731
How to Join This Clinical Trial - NCTNCT06503731
Learn how to participate in this PHASE2 trial studying an investigational therapy for Antibody-mediated Rejection. This study is currently enrolling participants.
Am I Eligible for This Clinical Trial?
This clinical research study is looking for participants with Antibody-mediated Rejection. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.
- Condition Being Studied
- Antibody-mediated Rejection
- Treatment Being Tested
- Investigational treatment
- Study Phase
- PHASE2 - Safety and effectiveness study
- Enrollment Status
- Currently enrolling participants
- Study Identifier
- NCTNCT06503731 - ClinicalTrials.gov Identifier
- Sponsored By
- Study sponsor
What to Expect as a Participant
Participating in this clinical trial involves:
- Initial screening to determine eligibility
- Regular study visits and health assessments
- Receiving the study treatment or placebo
- Medical monitoring and follow-up care
- Contributing to medical research that may help others
- Potential access to new treatments before they're widely available
Clinical Trial Benefits and Compensation
Participants in this clinical research study may receive:
- Close medical monitoring by healthcare professionals
- Access to potential new treatments
- Compensation for time and travel (varies by study)
- No-cost study-related medical care
- The opportunity to help advance medical knowledge
Where Is This Clinical Trial Located?
This study is enrolling participants at 20 locations. Find a study site near you:
Clinical Research Site
Birmingham, Alabama 35233 - United States
Status: RECRUITING
Clinical Research Site
Los Angeles, California 90048 - United States
Status: RECRUITING
Clinical Research Site
Durham, North Carolina 27705 - United States
Status: RECRUITING
Clinical Research Site
Columbus, Ohio 43210 - United States
Status: RECRUITING
Clinical Research Site
Richmond, Virginia 23298 - United States
Status: RECRUITING
Clinical Research Site
Seattle, Washington 98195 - United States
Status: RECRUITING
Clinical Research Site
Wien, 1090 - Austria
Status: RECRUITING
Clinical Research Site
Gent, 9000 - Belgium
Status: RECRUITING
Clinical Research Site
Leuven, 3000 - Belgium
Status: RECRUITING
Clinical Research Site
London, N6A 5A5 - Canada
Status: RECRUITING
And 10 more locations available. Contact us to find the nearest participating site.
How to Enroll in This Study
To learn more about participating in this PHASE2 clinical trial for Antibody-mediated Rejection:
- Review the eligibility criteria with your healthcare provider
- Contact the study team for a pre-screening interview
- Schedule an in-person screening visit if eligible
- Review and sign the informed consent form
- Begin participation in the clinical trial
Why Choose Quri.ai Study Finder
Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:
- Discover clinical trials before competitors
- Access exclusive contact information
- Track sponsor pipelines and opportunities
- Connect with decision makers directly
- Win more business partnerships